<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910618-0002</DOCNO><DOCID>910618-0002.</DOCID><HL>   Technology:   Bio-Technology Gets   EC Panel's Approval   For Growth Hormone</HL><DATE>06/18/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   BTGC DD MRK SBE</CO><MS>BASIC MATERIALS (BSC)CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>CHEMICALS, PLASTICS (CHM)DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>DELAWARE (DE)EUROPEAN COMMUNITY (EC)EUROPE (EU)ITALY (ITA)NEW JERSEY (NJ)NORTH AMERICA (NME)NEW YORK (NY)GREAT BRITAIN (UK)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   NEW YORK -- Bio-Technology General Corp. said a EuropeanCommunity regulatory panel recommended approval of itsversion of human growth hormone to treat short stature.   The company expects sales of the product, which islicensed to SmithKline Beecham PLC in Europe, to begin by theend of the year, after each of the 12 EC countries decideswhether to grant approval and pricing is negotiated.</LP><TEXT>   Bio-Technology will receive 30% of SmithKline's sales ofthe genetically engineered product, which will be sold underthe brand name Eskatrope. Eli Lilly andamp; Co., Genentech Inc. andSerono of Italy currently sell their versions of human growthhormone in some European countries.   Sim Fass, Bio-Technology president and chief executiveofficer, said he expects that in 1993 or 1994, revenue fromsales of the hormone &quot;will be sufficient to make usprofitable.&quot; In 1990, the development-stage company had aloss of $6.2 million, or 40 cents a share, on revenue of $4.3million.   In addition, Mr. Fass said, the company, as expected,completed its reacquisition from Du Pont-MerckPharmaceuticals of all rights for Bio-Technology's humangrowth hormone in the U.S. Bio-Technology issued 275,000shares of common valued at about $1 million, or a 1.3% stakein the company, to the Du Pont-Merck venture and agreed topay royalties of as much as $5 million on future productsales of human growth hormone.   Bio-Technology General doesn't expect to be able to marketthe drug in the U.S. before the end of 1994, when theprotected status held by Eli Lilly expires. Lilly's productis specifically protected for use in treating short stature.</TEXT></DOC>